A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase Clinical Trial

Official title:

A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With Chronic Myeloid Leukemia.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05367700
• Other study ID #: HS-10382-101
• Status: Recruiting
• Phase: Phase 1
• Start date: April 28, 2022
• Est. completion date: September 30, 2026

Study information

• Verified date: January 2023
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: Yu Hu
• Phone: 13986183871
• Email: dr_huyu[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

Description:

This is an open-label, multicenter, dose-escalation and expansion, first-in-human study in participants of CML with T315I mutation or without T315I mutation in chronic phase/accelerate phase(CP/AP). This study will consist of two parts: A part 1 dose escalation stage and a part 2 dose expansion stage. The objectives of this study are to evaluate the safety, tolerability, PK and preliminary anti-CML activity, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-10382. Participants with CML-CP/AP are eligible for dose escalation study if they had resistance to or unacceptable side effect from BCR-ABL1 TKIs. After determination of the MTD or the MAD for CML patients, dose expansion will be undertaken to further evaluate the efficacy and safety of HS-10382 in patients with CML-CP. All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression if the product is well tolerated and the subject has stable disease or better.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: September 30, 2026
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent form.

2. Men or women aged more than or equal to (=) 18 years, and less than (<) 75 years.

3. CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.

4. Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.

5. ECOG performance status of 0-2.

6. Life expectancy = 12 weeks.

7. Men or women should be using adequate contraceptive measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study.

8. Females must have evidence of non-childbearing potential.

Exclusion Criteria:

1. CML-CP patients who have acquired CCyR and have not lost it.

2. Patients with CML-CP who have progressed to AP or blast phase(BP.)

3. Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood.

4. Patients with CML-AP who have progressed to BP.

5. Previous treatment with a BCR-ABL1 TKI allosteric inhibitor .

6. Impaired cardiac function including any one of the following:

1. Resting corrected QT interval (QTc) > 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).

2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG.

3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,

4. Left ventricular ejection fraction (LVEF) = 50%.

5. During screening period, ECG examination showed average heart rate <50 beats per minute.

6. Myocardial infarction occurred within 6 months of the first scheduled dose of HS-10382.;

7. Congestive heart failure occurred within 6 months of the first scheduled dose of HS-10382.;

8. Uncontrollable angina.

7. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis

8. Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes).

9. Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.

10. Severe infection within 4 weeks prior to the first scheduled dose of HS-10382.

11. History of significant congenital or acquired bleeding disorders unrelated to CML.

12. Inadequate other organ function.

13. History of other malignancies.

14. History of hypersensitivity to any active or inactive ingredient of HS-10382.

15. History of neuropathy or mental disorders, including epilepsy and dementia.

16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

Related Conditions & MeSH terms

• CML, Chronic Phase
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid, Chronic-Phase

Intervention

Drug:
• HS-10382(Part 1: Dose escalation)
Single or multiple dose(s) of HS-10382 once daily.
• HS-10382(Part 2: Dose expansion)
HS-10382 is administered orally once daily.

Locations

Country	Name	City	State
China	Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1(Dose escalation): Maximum tolerated dose (MTD) for HS-10382	MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.	From the single dose to the last dose of the first cycle as 28days of multiple dosing (35days).
Primary	Part 2(Dose expansion): Major cytogenetic response (MCyR) rate at 6 months	MCyR is the proportion of patients achieving Complete cytogenetic response (CCyR: defined as 0% Philadelphia chromosome-positive [Ph+] metaphases by cytogenetic analysis of bone marrow) and Partial Cytogenetic Response (PCyR: defined as >0% to 35% Ph+ metaphases by cytogenetic analysis of bone marrow).	6 months
Secondary	Incidence and severity of treatment-emergent adverse events	Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, and NCI CTCAE v5.0.	From baseline until 28 days after the last dose.
Secondary	Observed maximum plasma concentration (Cmax) after single dose of HS-10382	From pre-dose to 120 hours after single dose on Day 1	In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10382 on Day 1 to Day 6.
Secondary	Time to reach maximum plasma concentration (Tmax) after single dose of HS-10382	In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10382 on Day 1 to Day 6.	From pre-dose to 120 hours after single dose on Day 1
Secondary	Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10382	Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.	From pre-dose to 120 hours after single dose on Day 1
Secondary	Hematologic response	Hematologic response will be assessed by complete blood count (CBC) and physical examination at each visit.	at screening and 28th day of cycle 1,2,3,4,5,6,9 and 12.
Secondary	Molecular response	Molecular response will be assessed by BCR-ABL1 transcript level as measured by RQ-PCR.	at screening and 28th day of cycle 3, 6, 9 and 12.
Secondary	Cytogenetic response	Cytogenetic response (CyR) is based on the prevalence of Ph+ cells in metaphase from bone marrow (BM) sample.	at screening and 28th day of cycle 3, 6, 9 and 12.
Secondary	Event-free survival (EFS)	EFS is defined as the time from the date of first dose to the earliest occurrence of the following events: death due to any cause ; loss of CHR ,loss of PCyR ;loss of CCyR ; discontinuation of study treatment due to AE or treatment failure ; progression to AP/BC .	up to 24 months
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the date of first dose to the earliest occurrence of progression to AP/BC or death from any cause.	up to 24 months
Secondary	Overall survival (OS)	OS is defined as the time from the date of first dose to the date of death from any cause.	up to 24 months